Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NuCoVac-11
- Development stage
- Unknown
- Lead developer
- Panacea Biotec
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
NuCoVac-11 is an 11-valent pneumococcal polysaccharide conjugate vaccine (PCV) developed by Panacea Biotec for the prevention of pneumonia and invasive pneumococcal diseases. The vaccine is designed to provide broad protection by targeting 11 specific serotypes of *Streptococcus pneumoniae*: 1, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. By conjugating these polysaccharides to a carrier protein, the vaccine stimulates a T-cell dependent immune response, which is particularly effective in infants and young children. NuCoVac-11 represents an expansion of Panacea Biotec's earlier 10-valent vaccine and is currently in Phase 3 clinical trials, where its safety and immunogenicity are being compared to Pfizer's Prevenar 13.
- Brand names
- NuCoVac-11NuCoVac11NuCoVac 11
- Other names
- 11-valent pneumococcal conjugate vaccine11-valent pneumococcal polysaccharide conjugate vaccine
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on NuCoVac-11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NuCoVac-11.